GENEVA--FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes ...

Alcon announced on October 16, 2026, that the U.S. Food and Drug Administration approved BRYTLY Redness Reliever Eye Drops, ...

Mizuho lowered its Alcon target from USD 85 to USD 80 on October 13, 2026, while keeping an Outperform rating, according to ...

Alcon received approval from the Food and Drug Administration for its Brytly eye drops. The company said Friday that it expects to make Brytly available for retail and online shopping in the coming ...

Alcon ( ALC ,ALC.SW) announced that the U.S. Food and Drug Administration approved BRYTLY Redness Reliever Eye Drops, an over-the-counter treatment designed to reduce eye redness.

Please provide your email address to receive an email when new articles are posted on . Alcon will buy Lensar’s outstanding shares for $14 per share. The deal is expected to close in the second half ...

Clareon PanOptix Pro provides more uninterrupted light distribution ...

Alcon Inc. gets upgraded to a Buy again after my prior hold rating. Upside could come from macro-level clinical demand in the eyecare niche, but also a diverse and growing product portfolio in both ...

Geneva, Switzerland-based Alcon and Orlando, FL-based Lensar have entered a merger agreement through which Alcon intends to acquire Lensar. The acquisition includes the Ally robotic cataract laser ...

Alcon has gained its first FDA nod for a prescription product since its 2019 split with Novartis, securing an approval for dry eye disease treatment Tryptyr. (Stock Photo ) Six years after being spun ...

I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $118 per share, despite a minor guidance cut. Alcon's new product launches, including PRECISION7 and Systane Pro, are ...